WINTON GROUP Ltd Has $1.11 Million Position in BioMarin Pharmaceutical Inc. $BMRN

WINTON GROUP Ltd reduced its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 84.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 18,720 shares of the biotechnology company’s stock after selling 104,754 shares during the period. WINTON GROUP Ltd’s holdings in BioMarin Pharmaceutical were worth $1,113,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of BMRN. NewEdge Advisors LLC boosted its position in shares of BioMarin Pharmaceutical by 11.5% during the first quarter. NewEdge Advisors LLC now owns 3,769 shares of the biotechnology company’s stock worth $266,000 after buying an additional 388 shares during the period. Empowered Funds LLC boosted its position in shares of BioMarin Pharmaceutical by 207.4% during the first quarter. Empowered Funds LLC now owns 12,023 shares of the biotechnology company’s stock worth $850,000 after buying an additional 8,112 shares during the period. Focus Partners Wealth boosted its holdings in BioMarin Pharmaceutical by 70.2% during the first quarter. Focus Partners Wealth now owns 11,817 shares of the biotechnology company’s stock worth $835,000 after purchasing an additional 4,876 shares during the last quarter. Sivia Capital Partners LLC boosted its holdings in BioMarin Pharmaceutical by 33.0% during the second quarter. Sivia Capital Partners LLC now owns 4,439 shares of the biotechnology company’s stock worth $244,000 after purchasing an additional 1,102 shares during the last quarter. Finally, Invesco Ltd. grew its position in BioMarin Pharmaceutical by 23.5% in the second quarter. Invesco Ltd. now owns 618,835 shares of the biotechnology company’s stock valued at $34,017,000 after purchasing an additional 117,617 shares in the last quarter. 98.71% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, EVP Gregory R. Friberg sold 3,281 shares of the firm’s stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $53.85, for a total value of $176,681.85. Following the completion of the sale, the executive vice president directly owned 51,818 shares in the company, valued at approximately $2,790,399.30. This trade represents a 5.95% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 0.85% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have issued reports on BMRN. Sanford C. Bernstein lowered their price target on shares of BioMarin Pharmaceutical from $94.00 to $82.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 5th. Jefferies Financial Group restated a “buy” rating and set a $103.00 price objective on shares of BioMarin Pharmaceutical in a research note on Thursday, March 12th. The Goldman Sachs Group initiated coverage on BioMarin Pharmaceutical in a report on Monday, May 11th. They issued a “neutral” rating and a $69.00 price objective for the company. Wall Street Zen downgraded BioMarin Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Saturday. Finally, HC Wainwright dropped their target price on BioMarin Pharmaceutical from $55.00 to $50.00 and set a “neutral” rating on the stock in a report on Monday, May 18th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and seven have assigned a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $88.67.

BioMarin Pharmaceutical Stock Performance

NASDAQ BMRN opened at $57.91 on Wednesday. The firm has a market capitalization of $11.19 billion, a P/E ratio of 42.27, a price-to-earnings-growth ratio of 0.43 and a beta of 0.25. The company has a current ratio of 5.81, a quick ratio of 4.20 and a debt-to-equity ratio of 0.23. The firm’s fifty day moving average price is $54.37 and its two-hundred day moving average price is $56.40. BioMarin Pharmaceutical Inc. has a 1 year low of $49.26 and a 1 year high of $66.28.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.